Blog Exposure – CHMP Adopts Positive Opinion for Alnylam’s Patisiran for HATTR Amyloidosis Treatment

Stock Monitor: Anika Therapeutics Post Earnings Reporting

LONDON, UK / ACCESSWIRE / July 31, 2018 / If you want access to our free research report on Alnylam Pharma, Inc. (NASDAQ: ALNY), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ALNY as the Company’s latest news hit the wire. On July 27, 2018, the Company announced that the Committee for Medicinal Products for Human Use (CHMP) has recommended a positive opinion recommending marketing authorization of patisiran for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adults with stage 1 or stage 2 polyneuropathy. If approved by the European Commission (EC), the medicine will be commercialized under the brand name ONPATTRO™. Register today and get access to over 1,000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is currently working on the research report for Anika Therapeutics, Inc. (NASDAQ: ANIK), which also belongs to the Healthcare sector as the Company Alnylam Pharma. Do not miss out and become a member today for free to access this upcoming report at:

www.active-investors.com/registration-sg/?symbol=ANIK

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Alnylam Pharma most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=ALNY

SmPC Recommended by CHMP Includes Data from APOLLO Primary and Secondary Endpoints

The CHMP’s positive opinion is based on the evaluation of the effects of patisiran in patients with hATTR amyloidosis and its safety profile as demonstrated in the APOLLO Phase-3 study. In APOLLO, the safety and efficacy of patisiran were evaluated in a diverse, global population of hATTR amyloidosis patients. The study showed that patisiran improved measures of polyneuropathy, quality of life, activities of daily living, ambulation, nutritional status, and autonomic symptoms relative to placebo in adult patients with hATTR amyloidosis. The SmPC recommended by the CHMP includes data from APOLLO primary and secondary endpoints, as well as exploratory cardiac endpoints. The results of the APOLLO study were published on July 05, 2018, in the New England Journal of Medicine (NEJM).

EC Will Review the CHMP’s Recommendation to Deliver its Final Decision

The European Medicines Agency (EMA) reviewed patisiran under the accelerated assessment procedure that is granted to medicines that the CHMP believes are of major interest for public health and therapeutic innovation. A CHMP positive opinion is one of the final steps before marketing authorization is granted by the EC. The EC will now review the CHMP recommendation to deliver its final decision, applicable to all 28 EU member states, plus Iceland, Liechtenstein, and Norway.

Patisiran is Currently Under Priority Review as a Breakthrough Therapy with the FDA

On February 01, 2018, the US Food and Drug Administration (FDA) accepted for filing its New Drug Application (NDA) for patisiran for the treatment of hATTR amyloidosis. The FDA also granted Alnylam’s request for Priority Review and has set an action date of August 11, 2018, under the Prescription Drug User Fee Act (PDUFA). Patisiran has been granted a Fast Track Designation, a Breakthrough Therapy Designation, and an expanded Orphan Drug Designation for ATTR amyloidosis from the FDA. Regulatory filings in other markets for patisiran, including Japan, are planned for mid-2018.

About Hereditary ATTR Amyloidosis

Hereditary ATTR (hATTR) amyloidosis is an inherited, progressive disease caused by a genetic mutation that results in the misfolding of transthyretin (TTR) proteins. This results in the formation of amyloid fibrils that could deposit in the nerves, heart, and/or gastrointestinal (GI) tract. hATTR amyloidosis symptoms can vary from person to person, depending on which organs or tissues are affected, and can worsen as the disease progresses. Many people remain undiagnosed or misdiagnosed and treatment options for people with this disease are limited.

About Patisiran

Patisiran is an investigational, intravenously administered ribonucleic acid interference (RNAi) therapeutic targeting transthyretin (TTR) in development for the treatment of hereditary ATTR amyloidosis. It is designed to target and silence specific messenger RNA, potentially blocking the production of TTR protein before it is made. This may help to reduce the deposition and facilitate the clearance of TTR amyloid in peripheral tissues and potentially restore function to these tissues.

About Alnylam Pharmaceuticals, Inc.

Founded in 2002 and headquartered in Cambridge, Massachusetts, Alnylam is a biopharmaceutical organization developing novel therapeutics based on RNAi. The Company is leading the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics in three strategic therapeutic areas (STArs), namely: (i) genetic medicines, (ii) cardio-metabolic diseases, and (iii) hepatic infectious diseases.

Stock Performance Snapshot

July 30, 2018 – At Monday’s closing bell, Alnylam Pharma’s stock declined 7.37%, ending the trading session at $96.81.

Volume traded for the day: 1.31 million shares, which was above the 3-month average volume of 731.68 thousand shares.

Stock performance in the previous three-month period – up 2.41%; and past twelve-month period – up 17.16%

After yesterday’s close, Alnylam Pharma’s market cap was at $9.85 billion.

The stock is part of the Healthcare sector, categorized under the Biotechnology industry.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

SOURCE: Active-Investors

ReleaseID: 507456